RankAlpha logo
Back to Rankings

RANI

Rani TherapeuticsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Further RT-114 data could strengthen the case for oral biologic delivery, while FDA technology-program engagement may help resolve manufacturing questions. Both remain prospective rather than validated commercial value.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Cash-runway guidance depends on spending and execution; further financing could dilute shareholders.
Momentum
85
Value
41
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.62 · Bull $1.05 · Bear $0.32Analysis 2026-10-22; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-22 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $7.20
Why
Momentum85 · Δ7d -
Value41 · Δ7d -0.1
Sentiment60 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Confirming evidence

  • • Sentiment remains the lead driver in the composite.

Contradictions & invalidation

  • • Cash-runway guidance depends on spending and execution; further financing could dilute shareholders.
  • • Initial RT-114 single-dose bioavailability does not establish repeat-dose efficacy, safety or commercial viability.
  • • RT-114 is early-stage; repeat-dose results, manufacturing scale-up and partner-dependent development could disappoint.

Catalyst clock

2026-12-31

RT-114 Phase 1a expansion data

Lead driver: Sentiment · See AI snapshot
Momentum
85
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
60
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade C. Momentum 84.6 / Value 40.6 / Sentiment 59.8

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-22. Scenario method

B+
Bull case
20%
Probability
Target price
$1.05
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
Most likely
B
Base case
55%
Probability
Target price
$0.62
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.32
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$84.46M
Beta
0.44
Shares Out
115.43M
P/E (TTM) · Derived
-1.6
P/S (TTM)
137.72
P/FCF (TTM) · Derived
-3.82
Rev YoY
+893.0%
EPS YoY
-78.4%
Gross Margin
+84.2%
Op Margin
-3727.8%
Net Debt
-$45.59M
Current Ratio
5.31
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data